| Methods |
Parallel design. Due to the randomisation method was not mentioned in original article, we telephone interviewed the trialist. The randomisation method was made clear that allocation sequence was generated by random number table. No blinding was performed. |
| Participants |
147 cases of Grave's disease were included (M/F=38/109, aged between 21 and 68, 31.4+/‐4.8 years old on average, with the length of the disease between 2 months and 6 years, 17 months on average). 49 cases were in radioiodine group (I), 49 cases were in tapazole group (T) and 49 cases were in jiakangxin with radioiodine group (J). |
| Interventions |
Radioiodine was used in both I and J groups, p.o., 3.70˜5.55 MBq, only once. The second day after taking radioiodine, Jiakangxin Koufuye was additionally given to the latter group, p.o., t.i.d., 20 mL each time, for 2 weeks. Tapazole was used in T group, p.o., 15˜30 mg/d, decreased the dosage 2 months later according to the changes of thyroxin. |
| Outcomes |
The outcomes were evaluated by total effective rate, on the basis of improvement of principal symptoms, body weight, thyroid hormones after 6 months.
1. Recovery: T/I/J=10/23/24;
2. Improvement: T/I/J=7/18/19;
3. Moderate improvement: T/I/J=11/1/4;
4. No improvement: T/I/J=21/7/2;
5. Total effective rate: T/I/J=57.1%/85.7%/91.7%. I group and J group had better effect than T group (P<0.05 );
6. Improvement of principal symptoms (including hidrosis, inertia, hyposomnia, dysphoria and limbs jitter): there was statistical significance between two groups, showing that 1˜3 months after the treatment, J group had better effects than I group. But there was no statistical significance between two groups 6 months after the treatment;
7. The level of FT3, FT4, TSH was better improved in I and J group than T group. There was statistical significance between two groups. |
| Notes |
1. Jiakangxin Koufuye was prepared by the author's hospital;
2. There's potential conflict of interest in the study. |
